The United States has spent two productive decades implementing a variety of prevention programs. While these efforts have slowed the rate of infection, challenges remain. The United States must refocus its efforts to contain the spread of HIV and AIDS in a way that would prevent as many new HIV infections as possible. No Time to Lose presents the Institute of Medicinea (TM)s framework for a national prevention strategy.
Committee on HIV Prevention Strategies in the United States, Division of Health Promotion and Disease Prevention, Monica S. Ruiz, Alicia R. Gable, Edward H. Kaplan, Michael A. Stoto, Harvey V. Fineberg, and James Trussell, Editors
1 Front Matter; 2 Executive Summary; 3 Introduction: Rethinking HIV Prevention; 4 Tracking the Epidemic; 5 Allocating Resources; 6 Using the Clinical Setting; 7 Translating Research into Action; 8 Searching for New Tools; 9 Overcoming Social Barriers; 10 Appendix A: The Changing Epidemic; 11 Appendix B: The Prevention Portfolio: Interventions to Prevent HIV Infection; 12 Appendix C: Federal Spending on HIV / AIDS; 13 Appendix D: Description and Mathematical Statement of the HIV Prevention Resource Allocation Model; 14 Appendix E: Data Gathering Activities; 15 Appendix F: Agendas for Public Committee Meetings; 16 Appendix G: Biographies; 17 Index
National Research Council, Division of Behavioral and Social Sciences and Education, Institute of Medicine, and Families Board on Children, Youth, Steve Olson
Institute of Medicine, Board on Population Health and Public Health Practice, Division of Health Promotion and Disease Prevention, Division of International Health
Institute of Medicine, Committee to Develop Methods Useful to the Department of Veteran Affairs in Estimating Its Physician Requirements, Joseph Lipscomb
National Research Council,Panel on Data and Research Priorities for Arresting AIDS in Sub-Saharan Africa, Panel on Data and Research Priorities for Arresting AIDS in Sub-Saharan Africa, National Research Council, Division of Behavioral and Social Sciences and Education, Commission on Behavioral and Social Sciences and Education, James Trussell, Barney Cohen
Institute of Medicine, Board on Global Health, Committee on the Methodological Challenges in HIV Prevention Trials, Alicia R. Gable, Stephen W. Lagakos
Institute of Medicine, Committee to Review the Adverse Consequences of Pertussis and RubellaVaccines, Harvey V. Fineberg, Cynthia J. Howe, Christopher P. Howson
Institute of Medicine, Committee on the Social and Ethical Impacts of Developments in Biomedicine, Harvey V. Fineberg, Elizabeth Meyer Bobby, Ruth Ellen Bulger
and Medicine National Academies of Sciences, Engineering, Health and Medicine Division, Board on Global Health, Board on Health Sciences Policy, Committee on Examining the Working Definition for Long COVID, Ilana Goldowitz, Tequam Worku, Lisa Brown, Harvey V. Fineberg
National Research Council, Division of Behavioral and Social Sciences and Education, Board on Environmental Change and Society, Committee on Risk Characterization, Harvey V. Fineberg, Paul C. Stern